OxOnc Development is a virtual oncology development company that was formed in 2012 by experienced pharmaceutical and clinical development executives. The drug development model is based on the expertise and core competencies of the OxOnc Development team to optimally design and execute clinical trials in oncology.

The OxOnc business model is an integration of scientific, clinical, operational and financial resources, and provides a clear value-add proposition to our co-development partner by providing a P&L-sparing mechanism to fund R&D efforts externally. The model also allows parallel development in other regions outside of the US or EU, or for certain tumor types that are prevalent in a particular ethnic group.

OxOnc is funded by Orbimed Advisors, a leading venture capital group in life sciences with $6 billion under management.

OxOnc recently announced that it has entered into a co-development agreement with Pfizer Inc., to conduct a pivotal clinical trial of Pfizer's crizotinib, marketed under the trademark Xalkori ®, for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring a ROS1 (c-ros) gene rearrangement (ROS1-positive). The study will take place in Japan, China, South Korea and Taiwan.